Sight Sciences Inc (SGHT)

looking strong again

Sight Sciences wins $34M patent ruling against AlconMarch 30, 2026 8:26 AM
IH Market News
Sight Sciences Inc. (NASDAQ:SGHT) has obtained a court order confirming a jury’s finding that Alcon Inc. willfully infringed three patents related to glaucoma treatment technology. The order was issued on March 27, 2026, by the U.S. District Court for the District of Delaware.The ruling grants Sight Sciences $34 million in damages. This includes $5.5 million in lost profits and $28.5 million in royalty payments tied to Alcon’s Hydrus Microstent sales from the product’s commercial launch up to the jury verdict. In addition, the court ordered an ongoing royalty equal to 10% of Hydrus revenue through November 10, 2028, when the final patent involved in the case expires.The lawsuit, first filed on September 16, 2021, centered on three Sight Sciences patents: U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328. The jury determined that Alcon’s Hydrus Microstent device infringed each of these patents.A final judgment will be issued once supplemental damages and pre-judgment interest are calculated using additional financial data from Alcon. The decision can still be appealed by Alcon and could also be influenced by ex parte reexamination proceedings the company initiated with the U.S. Patent and Trademark Office.“We are pleased with the results of the ruling and the recognition of our strong intellectual property portfolio in interventional glaucoma,” said Paul Badawi, co-founder and chief executive officer of Sight Sciences.Sight Sciences said it expects to record a $5.4 million success fee as an operating expense, payable to law firm Cooley LLP, which represented the company in the case. The company indicated that this fee will be excluded from its non-GAAP adjusted operating expense calculations.Sight Sciences stock price

Original: Sight Sciences wins $34M patent ruling against Alcon

Below four dollars???

Looking like the stock lost its steam!

CLOSED TODAY AT A 30 MONTH HIGH PPS

UBS UPDATED THEIR TARGET TO $12

$9.05
+ $0.61
+ 7.23%

Another 52 week high
$8.53
+ $0.48
+ 5.96%

Another 52 week high PPS.
$8.39
+ $0.29
+ 3.58%

Sure beats waiting decades for SFRX. Those clueless minions will go to their graves, waiting for the impossible to happen.

Hit a new 52 week high today.
Closed above $8.

Was $3 just $6 weeks ago

Nice bounce yesterday. Up 10%

SGHT UP BIG, AGAIN
$7.72
+ $0.68
+ 9.66%

SGHT UP BIG, AGAIN

$7.04
+ $0.52
+ 7.98%

MORE GREAT NEWS

New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans
Sight Sciences, Inc.
Tue, November 11, 2025

Sight Sciences, Inc.
Sight Sciences, Inc.
Prospective study data and retrospective registry data were analyzed in the manuscripts recently published by the Journal of Cataract and Refractive Surgery, Journal of Glaucoma and Clinical Ophthalmology

MENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today the results from three key published manuscripts that further demonstrate the value of an interventional mindset in treating glaucoma.


“We are proud to continuously support the study of interventional glaucoma treatment, especially in highlighting critical groups of patients that may benefit from active surgical interventions. These results demonstrate that when surgeons are given the right solutions, they are able to reduce a patient’s intraocular eye pressure (IOP) and reliance on medication and maintain those reductions over an extended period of time, 24 months or 36 months,” said Paul Badawi, Founder and Chief Executive Officer of Sight Sciences.

The following are notable results from the studies:

In a 24-month prospective study of 18 eyes with medication washout at baseline, 12 and 24 months, of standalone OMNI use, mean baseline IOP of 26.1 mmHg was reduced an average of 9.7mmHg at 12 months and 10.6 mmHg at 24 months (both p

SGHT UP BIG, AGAIN

$6.52
+ $0.70
+ 12.03%

SGHT up nearly 100% over the last month

New appointments: https://investors.sightsciences.com/news-releases/news-release-details/sight-sciences-appoints-ali-bauerlein-chief-operating-officer

A great Quarter: https://finance.yahoo.com/news/sight-sciences-reports-third-quarter-210500201.html

$5.28 +$0.07 (+1.34%)

The above reflects only 2 of the Medicare Administrative Contractors granting approval for reimbursement on TearCare.

The states and regions covered by these two MACS have 10.4 million in estimated total covered lives and represents only 30% of the total Medicare fee-for-service covered lives

NEWS! https://investors.sightsciences.com/static-files/ac22faa9-202d-46bb-a1a8-3c650cd72b4b

4.6900
+1.2400
+(35.94%)

https://www.sightsciences.com/us/tearcare/

Big news and a nice price jump. https://finance.yahoo.com/news/sight-sciences-announces-fee-schedule-110000136.html

Nice jump yesterday.

Lake Street Capital Markets upgraded Sight Sciences Inc. (NASDAQ:SGHT) from Hold to Buy with a price target of $5.00 on Friday. The stock has shown strong momentum, gaining over 8.5% in the past week and trading at $4.13, according to InvestingPro data.

at 3$ again
will Staffan buy shares again?

I expected it and I bought puts in advance of it.
Was easy to predict

Exactly 1 year since the PPS tanked to $1
Which meant that those who held for 1 year to get LTCGT were going to dump

Wow! Big dip today. What is up?

Hmmm below the professionals price estimate of 5.70. Interesting. I guess you were right on that not being correct. It’s looking like it is below 5.70 .,,,

Hmmm below the professionals price estimate of 5.70. Interesting. I guess you were right on that not being correct. It’s looking like it is below 5.70 .,,,

GOOD NEWS

https://finance.yahoo.com/news/single-tearcare-treatment-improved-functional-200500005.html

Nice movement today

Imagine that , it’s back to target price. Maybe the pro knows something about it after all?!

It’s just hit $5.70

It’s closing in on the target price

Hopefully it will bounce back
It beat estimated revenue

Hopefully it will bounce back

Lots of trading post and premarket. Could be another good day. Earnings to be reported on 8/1

https://finance.yahoo.com/news/sight-sciences-report-second-quarter-200500099.html

Looking awesome. Getting close to a 52 week high PPS. I'm up nearly 200% on my $2.98's.

TFSBIGWS!!!

Do you think that hold is referring to not buying the stock? Is that a possibility?

I love the way you have to dialogue with inflammatory language.

Do you think that hold is referring to not buying the stock? Is that a possibility?

I love the way you have to dialogue with inflammatory language.

Only a fool would listen to an analyst who advises holding a stock that's trading $2.25 ABOVE their price target.
CURRENT PRICE $7.95
Price Target $5.70
ANALYST RATING:
HOLD

Oh NO!!!

47,780 shares? Out of the millions they own????

The world is coming to an end!!!

https://finance.yahoo.com/quote/SGHT/insider-roster/

Re: the buyout you speculated about

I’m guessing that Alison Bouerlein, CFO
Jeremy Hayden , David Badawi, CTO, Paul Badawi CEO, and Sam Park CTO who are officers of sght did not know about the merger either.
They all sold shares July 1, 2 2024

47,780 shares at 5.42 to 6.21 average price per share

they're

Oh no, not another UP day!! How many am I supposed to endure?

UP $0.49
+6.27%

ANOTHER 11 month high closing PPS!

Boy- those analysts sure do know what their talking about, don't they!?!?

I guess they don’t know about the buyout:


According to marketbeat:


UPSIDE/ DOWNSIDE
27.1% Downside
$5.70 Price Target

SHORT INTEREST
Bearish
4.09% of Float Sold Short

ANALYST RATING
Hold
2.00 Rating Score

(Sight Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 5 hold ratings, and 1 sell rating.)

INSIDER TRADING
Selling Shares
$290,061 Sold Last Quarter

Overall marketrank
0.50 out of 5 stars

What happened?

Sight Sciences sets terms for IPO, to raise up to $160.5 million
Published: July 8, 2021 at 6:37 a.m. ET

Sight Sciences Inc. has set terms of its initial public offering, which could value the California-based ophthalmology and optometry company at up to $971.7 million. The company is looking to raise up to $160.54 million, as it is offering 6.98 million shares in the IPO, which is expected to price between $20 and $23 a share.

LOL

Up nearly 3%

Closed at the 11 month high pps

lol

I put more weight into my own projection- that SGHT will be acquired by a larger optical device company, like Alcon, against whom SGHT was recently awarded damages for patent infringement.

https://www.healio.com/news/ophthalmology/20240430/sight-sciences-awarded-34-million-in-patent-infringement-case-against-alcon

Here’s where I got the information:

Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · IEX Real-Time Price · USD

Price Target
5.60 (-27.18%)

Not my analysis, just researching what various experts have suggested about the potential stock movements of sght.

Three different sources have said not to buy and multiple sources have said year price around $6.

What do you think about the fact that the projected profitability is three years away at best?